Virtual Primary Care / Direct-to-Consumer Telehealth
Strategic Profile
LifeMD is building a platform patients can return to for more of their healthcare needs over time, making this business more durable. The company operates a 50-state medical benefits infrastructure expected to cover 220 million Americans, a specialized affiliated provider group, and a national affiliated pharmacy operation. Key competitive differentiation includes AI integration, compounding pharmacy capabilities, and strategic partnerships with major pharmaceutical brands.
Cyborg Score Rationale
LifeMD added over 42,000 net telehealth subscribers in Q1 2026—its largest quarterly net addition in history—ending the quarter with over 365,000 subscribers. The company exited Q1 2026 with $34.5 million of cash and no debt while affirming full year 2026 guidance for revenue of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million. Growth momentum is strong, though the business remains pre-profitable on a GAAP basis.
Top Insights
Women's Health patient signups showed 657% quarter-over-quarter growth with approximately 70% reduction in customer acquisition costs, demonstrating scalable unit economics
The women's health business focused on menopause, hormonal, and bone health is seeing encouraging early patient growth in an underserved population
Women's Health segment achieved a 657% QoQ growth in patient signups while reducing CAC by 70%, indicating product-market fit and improving economics
AI, pharmacy, and insurance are becoming real levers for better care, stronger retention, and margin expansion, with margin impact expected to become more visible in 2026
Named Competitors
Ro — Direct-to-consumer telehealth for multiple conditions
Amazon Clinic — Virtual primary care powered by Amazon infrastructure
GoodRx Health — Telehealth platform with pharmacy price transparency
Recent Developments
(May 2026) Q1 2026 earnings: Delivered $50.2 million revenue ahead of guidance with record 42,000+ net new subscribers
(January 2026) Closed $50 million revolving credit facility with Citizens Bank with maturity in January 2029
(March 2026) Reaffirmed 2026 guidance of $220–230 million revenue (13–19% YoY growth) and $12–17 million adjusted EBITDA with annualized run-rate expected to exceed $250 million
Open the full interactive LifeMD, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.